macular oedema

This page shows the latest macular oedema news and features for those working in and with pharma, biotech and healthcare.

After Lucentis setback, Novartis trumpets data on follow-up drug

The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD), ... In addition to nAMD, Novartis

Latest news

Regeneron and Bayer drop AMD combination

Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival Novartis. ... advance the duo into phase III in either AMD or diabetic macular oedema.
Lucentis claims speedy FDA review for myopia complication

in the EU myopic CNV market, adding to their rivalry in other indications such as wet age-related macular degeneration and diabetic macular oedema.
NICE backs Bayer’s Eylea as first-line BRVO treatment

This treatment continues to achieve positive results in real-life clinical practice, similar to that demonstrated in clinical trials, and we hope that this will continue for patients with macular oedema ... its rivals in macular oedema Roche's Avastin
NICE gives Bayer's Elyea a provisional 'no' for first-line use

The provisional guidance in NICE's Appraisal Consultation Document only recommends Eylea in visual impairment in adults caused by macular oedema if laser photocoagulation has not been beneficial or is not ... NICE has previously recommended Eylea to
NICE backs Bayer's Eylea in diabetic eye condition

Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema (DMO). ... It also represents Eylea's third NICE recommendation, following positive guidance for wet age-related macular

More from news
Approximately 8 fully matching, plus 43 partially matching documents found.

Latest Intelligence

Medius Deal Watch table for February 2015

Majority acquisition. 380. Pfenex/ Hospira. PF582 - LUCENTIS biosimilar candidate - wet age-related macular degeneration, diabetic macular oedema.
Allergan and taking a specialised approach

spasticity associated with stroke and for the ophthalmology treatment Ozurdex in diabetic macular oedema.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Systematic Review Lead- London: Negotiable

Healthcare PR Director: £100, 000 – £120, 000 benefits

Medical Writer - Creative and Scientific Projects: DOE

Account Manager- 4 days per week or full-time: Salary TBC

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director or Senior Account Director: Salary TBC

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Medical Writer: Salary is DOE

Account Manager: Negotiable

Market Access Consultant - Greater Manchester: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Account Manager – Healthcare Advertising: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Graduate Scientific Editor: DOE

Associate Scientific Director: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Writer, Healthcare Advertising, London: Excellent package

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...